Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

L.A. McKeown

June 08, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

Intravascular Lithotripsy May Facilitate TAVI in Patients With PAD

L.A. McKeown

November 04, 2021

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Industry News

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

April 24, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

Advertisement

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Intravascular Lithotripsy May Facilitate TAVI in Patients With PAD

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

FDA’s First Take on New Paclitaxel Concerns in CLI

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content